Table 1.
Nanog knockdown inhibits tumor development
| Experimentsa | Tumor incidenceb | Weight (g)c | P valuesd |
|---|---|---|---|
| Du145 (75k/injection; 56d) | |||
| pLL3.7 | 8/8 | 0.25 ± 0.05 | |
| Nanog-shRNA | 8/8 | 0.13 ± 0.07 | 0.02 |
| Du145 (10k/injection) | |||
| pLL3.7 (62d) | 7/8 | 0.71 ± 0.45 | |
| Nanog-shRNA (62d) | 7/8 | 0.32 ± 0.18 | 0.045 |
| Du145 (25k/injection; 63d) | |||
| pGIPZ-control | 9/10 | 0.50 ± 0.32 | |
| pGIPZ-Nanog | 6/10* | 0.22 ± 0.27 | 0.038 |
| LAPC9 (1k/inj; 60d) | |||
| pLL3.7 | 6/6 | 1.03 ± 0.25 | |
| Nanog-shRNA 1* | 5/6 | 0.04 ± 0.03 | 0.04 |
| Nanog-shRNA 2* | 5/6 | 0.076 ± 0.07 | 0.04 |
| LAPC4 (150k/inj; 67d) | |||
| pLL3.7 | 6/6 | 0.08 ± 0.05 | |
| Nanog-shRNA | 5/6 | 0.02 ± 0.008 | 0.017 |
| TRC Nanog-shRNA | 2/6** | 0.02 ± 0.001 | 0.01 |
| HPCa18 (100k/TR; 150d)# | |||
| pLL3.7 | 2/2 | N/A | |
| Nanog-shRNA | 0/2 | N/A | |
| MCF7 (100k/injection; 97d) | |||
| pLL3.7 | 9/10 | 0.45 ± 0.13 | |
| Nanog-shRNA | 8/10 | 0.09 ± 0.02 | 0.028 |
| TRC Nanog-shRNA | 9/10 | 0.05 ± 0.016 | 0.012 |
| Oct4-shRNA | 9/10 | 0.20 ± 0.03 | 0.1 |
| Nanog-shRNA + Oct4-hRNA | 7/10 | 0.06 ± 0.014 | 0.029 |
| Colo320 (25k/injection; 35d) | |||
| pLL3.7 | 5/5 | 0.11 ± 0.07 | |
| Nanog-shRNA | 3/5* | 0.076 ± 0.02 | 0.042 |
| Colo320 (250k/injection; 35d) | |||
| pLL3.7 | 8/8 | 0.82 ± 0.38 | |
| Nanog-shRNA | 4/8** | 0.058 ± 0.008 | 0.003 |
| Oct4-shRNA | 7/8 | 0.26 ± 0.19 | 0.006 |
| Colo320 (250k/injection; 34d) | |||
| pLL3.7-luciferase | 8/8 | 0.77 ± 0.48 | |
| Nanog-shRNA | 2/8** | 0.67 ± 0.17 | 0.79 |
| Oct4-shRNA | 8/8 | 0.52 ± 0.41 | 0.29 |
Cultured cancer cells or xenograft-purified cells were infected with the indicated lentiviral vectors at an MOI of 20.24–48 h after infection, different numbers (k) of cells were injected subcutaneously in Matrigel (50%) into NOD/SCID mice. Termination time in days (d) is indicated in parentheses.
The asterisks (*) indicate two independent infections of LAPC9 cells in the same experiment.
For HPCa18 (#), 100,000 infected cells were recombined with 200,000 rUGM cells and transplanted under the kidney capsule and the tissue recombinants (TR) were harvested 5 months later.
Number of tumors developed/number of injections.
P < 0.05;
P < 0.01 (χ2 test).
Mean ± S.D. N/A, not available.
Statistical comparisons (Student t-test) for tumor weights were made with the control (pLL3.7, pGIPZ-control or pLL3.7-luciferase) group.